Your SlideShare is downloading. ×
Okyanos Heart Institute Stem Cell Therapy Educational Seminar
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Okyanos Heart Institute Stem Cell Therapy Educational Seminar

142
views

Published on

Okyanos Heart Institute treats patients with coronary artery disease with their own stem cells. This presentation is part of a free educational seminar. More information can be found at …

Okyanos Heart Institute treats patients with coronary artery disease with their own stem cells. This presentation is part of a free educational seminar. More information can be found at http://www.okyanos.com

Published in: Health & Medicine, Technology

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
142
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. A FAMILY GUIDE TO CARDIAC STEM CELL THERAPY Restore Flow; Restore Life
  • 2. Interventional Cardiologist, over 25 years • University of Georgia, BS • Medical College of Georgia, M.D. • Emory University, MBA. • Vanderbilt University, Fellowship Former Chief, Cardiac Sciences, Saint Thomas Hospital, Nashville, Tennessee American College of Cardiology, Trustee American Heart Association, Former President, Davison County Chapter Howard T. Walpole, M.D. Chief Medical Officer Okyanos Heart Institute More than 17,000 cardiac catheterizations Howard T. Walpole, MD, MBA, FACC, FACAI Chief Medical Officer
  • 3. Leslie Miller, MD, FACC Chief Science Officer, Okyanos Chair, Department of Cardiovascular Medicine, University of South Florida (USF) Director/CEO , USF Cardiovascular Clinical and Research Integrated Strategic Program World-renowned cardiologist, specifically in the areas of heart failure and transplant. Former Director, Cardiac Programs, Georgetown University School of Medicine, Georgetown University Hospital and Washington Hospital Center. Professor/Director, Cardiovascular Division, University of Minnesota. Investigator in over 80 clinical trials including the use of adipose-derived stem and regenerative cells for the treatment of cardiovascular disease.
  • 4. Gretchen Dezelick, RN, BSN, CNOR, LHCRM Director of Nursing Over 25 years of nursing experience Certified Critical Care Nurse (CCRN) for more than 20 years Certified Peri-Operative Nurse (CNOR) Licensed Healthcare Risk Manager (LHCRM) Oversees care delivery & safety standards Represents nursing as a member of the senior leadership team R.N., St. Joseph Hospital School of Nursing, Lancaster, PA BSN, Millersville State University, PA • American Association of Critical Care Nurses • Association for Professionals in Infection Control • Association of Peri-Operative Registered Nurses • Florida Society of Healthcare Risk Managers • American Society for Healthcare Risk Management and Ambulatory Surgery Center Association.
  • 5. Beyond Bypass Surgery and Stents Cell Therapy is the Next Generation of Medicine
  • 6. Okyanos Heart Institute
  • 7. Medical Advisory Council Eric Duckers, MD, PhD, FESC, FACC Erasmus University, Netherlands Leslie Miller, MD, FACC University of South Florida Farrell Mendelsohn, MD, FACC Center for Therapeutic Angiogenesis Antonio Colombo, MD, FACC Columbus Hospital, San Raffaele Hospital
  • 8. Evolution of Medicine Cardiac stem cell therapy promises to be a new phase in the treatment of coronary artery disease. Past Future
  • 9. Ischemic Diseases Stroke Cardiac Diabetic Wounds PVD Radiation and Other Chronic Wounds
  • 10. 10 EU FDA EU Ahead of FDA with Comparable Safety An English Speaking Country Recognizing European Union (EU) Standards Convenient to No-Option Patients
  • 11. The Clinical Trials Demonstrates Safety and Better Quality of Life
  • 12. PRECISE: Sustained Functional Benefit Direct Injection Into Heart Muscle via Catheter 19 15.5 15.3 16.6 17.2 17.1 14.0 15.0 16.0 17.0 18.0 19.0 20.0 Baseline 6 Months 18 Months Control Cell MVO2(%) p < 0.05 p < 0.05 Transplant
  • 13. Okyanos Treatment • Unique mixture of stem and regenerative cells. Trial evidence demonstrates that new blood vessels begin, and damaged heart muscle starts to heal itself. • Boosts your body's ability to heal itself. • Delivered via a catheter into the heart for optimal placement vs. a syringe passing through bloodstream. • Derived from adipose tissue with 2400 times more stem cells than from bone marrow. •Only EU Approved cell-processing device available today.
  • 14. Adipose Derived Regenerative Cells (ADRCs) Celution™ is an approved European Union cell processing device. “Fresh cells from adipose- tissue using the Celution™ system seems to have the most dramatic results of any cell therapy study I have seen in Chronic Ischemic Heart Disease.” Francisco Fernandez-Aviles MD, PhD
  • 15. We Know.. Many Trial Patients Are Living Better & Longer than Expected Cardiac Cell Therapy is Not (Yet) a “Cure”
  • 16. Not dancing isn’t an option
  • 17. Are You a Candidate?
  • 18. When to consider cell therapy?  For continuing symptoms of heart failure despite bypass surgery and/or stents, such as shortness of breath and chest discomfort.  In patients with progressively worsening heart function with or without symptoms.  For patients with evidence of inadequate cardiac blood flow.
  • 19. A Partnership with Your Physician
  • 20. Full Medical Screening
  • 21. 22 Minute Flight From Florida to Freeport, Bahamas Day 1
  • 22. Visit Okyanos Heart Institute Clinic Day 2
  • 23. Procedure Day Day 3
  • 24. Day of Rest Day 4
  • 25. Final Clinic Visit & Return Home Day 5
  • 26. Determination For a Better Quality of Life With Cardiac Cell Therapy
  • 27. U.S. cardiology team quality of life research sterile, modern cath lab easy access short recovery a new standard of care